Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Neoleukin Therapeutics, Inc. | d342545dex322.htm |
| EX-32.1 - EX-32.1 - Neoleukin Therapeutics, Inc. | d342545dex321.htm |
| EX-31.2 - EX-31.2 - Neoleukin Therapeutics, Inc. | d342545dex312.htm |
| EX-31.1 - EX-31.1 - Neoleukin Therapeutics, Inc. | d342545dex311.htm |
| 10-K - 10-K - Neoleukin Therapeutics, Inc. | d342545d10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statements Nos.333-194490, 333-203179 and 333-210172 on Form S-8 and Nos. 333-203180, 333-208651 and 333-215457 on Form S-3 of our report dated March 9, 2017, relating to the consolidated financial statements of Aquinox Pharmaceuticals, Inc. and subsidiary appearing in this Annual Report on Form 10-K of Aquinox Pharmaceuticals, Inc. for the year ended December 31, 2016.
/s/ Deloitte LLP
Chartered Professional Accountants
Vancouver, Canada
March 9, 2017